Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

Alzheimer's, addiction, cardiovascular diseases, kidney disorders, sleep apnoea, diabetes, obesity, and overweight.

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

Plenty of people want to lose weight in 2025, but here's why many may actually get there thanks to GLP-1 drugs.

GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their developers with both rich remuneration and scientific acclamation. There are now ...

Starting in the new year, Independence Blue Cross, the region’s largest health insurer, will no longer cover anti-obesity drugs like Ozempic and Wegovy when they’re prescribed solely for weight loss.

Director-General of the World Health Organization, Tedros Adhanom Ghebreyesus, says he was close to the departure lounge when it was hit. Ukraine's air force says it detected 184 missiles and ...